Anne Sophie Kubasch

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 354 citations

Medicine, Hematology, Pharmacology +17

Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1β expression and release

Sigrun R. Hofmann, Anne Sophie Kubasch, Christina Ioannidis et al. · Clinical Immunology · 2015 · 119 citations

Life Sciences, Cell Biology, Immunology +13

CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease

Judith S. Hecker, Luise Hartmann, Jennifer Rivière et al. · Blood · 2021 · 97 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +11

Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO)

Sigrun R. Hofmann, Anne Sophie Kubasch, Ursula Range et al. · Rheumatology International · 2016 · 88 citations

Medicine, Pathology, Bone Metabolism +10

A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome

Sabrina Bondu, Anne‐Sophie Alary, Carine Lefèvre et al. · Science Translational Medicine · 2019 · 80 citations · Full text

Medicine, Genetics, Hematology +17